0 442

Cited 2 times in

Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer

DC FieldValueLanguage
dc.contributor.author임종근-
dc.contributor.author정현철-
dc.contributor.author정희철-
dc.contributor.author노성훈-
dc.contributor.author노재경-
dc.contributor.author라선영-
dc.contributor.author신상준-
dc.contributor.author안중배-
dc.date.accessioned2015-04-24T16:34:56Z-
dc.date.available2015-04-24T16:34:56Z-
dc.date.issued2009-
dc.identifier.issn1019-6439-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/103784-
dc.description.abstractAnemia is a unique side effect in Korean gastric cancer patients after S-1 monotherapy. We studied gastric cancer patients from a phase II trial of S-1 monotherapy with a 2-week treatment and 1-week rest schedule. Patients from a phase II trial of S-1 monotherapy with a 4-week treatment and 2-week rest were used as a reference group. The patients were categorized into two groups based on the degree of hemoglobin reduction per cycle of S-1: the mild reduction group (MRG DeltaHb/cycle < or =1.0) or severe reduction group (SRG DeltaHb/cycle >1.0). DeltaHb/cycle was calculated from maximum reduction of hemoglobin per one cycle of the treatment. Microarray-CGH was performed using a 17K cDNA microarray containing 15,723 unique genes. We selected genes with copy number variation defined as amplification (log2R/G >0.68) or deletion (log2R/G <-0.68), and a genetic aberration frequency difference of > or =30% between the MRG and the SRG. There were no differences in clinical factors, S-1 treatment-related factors (dose, dose intensity), toxicity, S-1 metabolism-related gene copy numbers (CYP2A6, DPD), or progression-free survival between the MRG and the SRG. Three genes were selected from microarray-CGH and logistic regression model: logit LN(Z) = (1.321) + (1.038 x PTX1) + (0.211 x MYO5A) + (0.516 x ZNF664). In the SRG, all 3 genes showed a trend of higher copy numbers than the MRG. There were no common anemia-related genes identified from different chemotherapy schedule of S-1 monotherapy. The logistics obtained from 3 genes predicted the hemoglobin reduction with an accuracy of 78%. The AUC was 0.744 for the final regression model. The combined copy number changes of the 3 genes can be developed into a biomarker in predicting S-1 treatment-related anemia.-
dc.description.statementOfResponsibilityopen-
dc.format.extent787~796-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAnemia/blood-
dc.subject.MESHAnemia/chemically induced*-
dc.subject.MESHAnemia/genetics-
dc.subject.MESHAntimetabolites, Antineoplastic/adverse effects*-
dc.subject.MESHAntimetabolites, Antineoplastic/therapeutic use-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHDrug Combinations-
dc.subject.MESHFemale-
dc.subject.MESHGene Dosage*-
dc.subject.MESHHemoglobins/metabolism*-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOxonic Acid/adverse effects*-
dc.subject.MESHOxonic Acid/therapeutic use-
dc.subject.MESHStomach Neoplasms/blood*-
dc.subject.MESHStomach Neoplasms/drug therapy*-
dc.subject.MESHStomach Neoplasms/genetics-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTegafur/adverse effects*-
dc.subject.MESHTegafur/therapeutic use-
dc.subject.MESHTreatment Outcome-
dc.titleCopy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorHEI CHEUL JEUNG-
dc.contributor.googleauthorSUN YOUNG RHA-
dc.contributor.googleauthorCHAN HEE PARK-
dc.contributor.googleauthorCHONG-KUN IM-
dc.contributor.googleauthorSANG JOON SHIN-
dc.contributor.googleauthorJOONG BAE AHN-
dc.contributor.googleauthorSUNG HOON NOH-
dc.contributor.googleauthorJAE KYUNG ROH-
dc.contributor.googleauthorHYUN CHEOL CHUNG-
dc.identifier.doi10.3892/ijo_00000204-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03402-
dc.contributor.localIdA03773-
dc.contributor.localIdA01281-
dc.contributor.localIdA01290-
dc.contributor.localIdA02105-
dc.contributor.localIdA02262-
dc.contributor.localIdA03794-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ01141-
dc.identifier.eissn1791-2423-
dc.identifier.pmid19212683-
dc.identifier.urlhttp://www.spandidos-publications.com/ijo/34/3/787?text=abstract-
dc.contributor.alternativeNameIm, Chong Kun-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.alternativeNameRoh, Jae Kyung-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.alternativeNameAhn, Joong Bae-
dc.contributor.affiliatedAuthorIm, Chong Kun-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorNoh, Sung Hoon-
dc.contributor.affiliatedAuthorRoh, Jae Kyung-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.contributor.affiliatedAuthorAhn, Joong Bae-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.citation.volume34-
dc.citation.number3-
dc.citation.startPage787-
dc.citation.endPage796-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF ONCOLOGY, Vol.34(3) : 787-796, 2009-
dc.identifier.rimsid36692-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.